Reduction of etoposide induced cell killing by hyperthermia can occur without changes in etoposide transport or DNA topoisomerase II activity

References

• Armour E. P., McEachern D., Wang Z., Corry P., Martinez A. Sensitivity of human cells to mild hyperthermia. Cancer Research 1993; 53: 2740–2744
   PubMed Web of Science ®Google Scholar
• Barlogie B., Corry P. M., Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammine platinum (II) and mitomycin C. Cancer Research 1980; 40: 1165–1168
   PubMed Web of Science ®Google Scholar
• Berrios M., Osheroff N., Fisher P. A. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophilia nuclear matrix fraction. Proceedings of the National Academy of Sciences, USA 1985; 82: 4142–4146
   PubMed Web of Science ®Google Scholar
• Bichay T. J., Feeley M. M., Raaphorst G. P. A comparison of heat sensitivity, radiosensitivity and PLDR in four human melanoma cell lines. Melanoma Research 1992; 2: 63–69
   PubMed Web of Science ®Google Scholar
• Brill S. J., Dinardo S., Voelkel-Meinan K., Sternglanz R. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature 1987; 326: 414–416
   PubMedGoogle Scholar
• Chen M., Beck W. T. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Research 1993; 53: 5946–5953
   PubMed Web of Science ®Google Scholar
• De Jong S., Kooistra A. J., van Vries E. G. E., Mulder N. H., et al. Topoisomerase II as a target of VM-26 and 4′-(9-acridinylamino) methanesulfon-maniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Research 1993; 53: 1064–1071
   PubMedGoogle Scholar
• Dewhirst M. Future directions in hyperthermic biology. International Journal of Hyperthermia 1994; 10: 339–345
   PubMed Web of Science ®Google Scholar
• Dinardo S., Voelkel K., Sternglanz R. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proceedings of the National Academy of Sciences, USA 1984; 81: 2616–2620
   PubMed Web of Science ®Google Scholar
• Dynlacht J. R., Wong R. S. L., Albright N., Dewey W. C. Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase II-DNA cleavable complexes. Cancer Research 1994; 54: 4129–4137
   PubMed Web of Science ®Google Scholar
• Earnshaw W. C., Halligan B., Cooke C. A., Heck M. M. Toposisomerase II is a structural component of mitotic chromosome scaffolds. Journal of Cell Biology, 100: 1706–1715
   PubMedGoogle Scholar
• Eppelbaum R., Teicher B. A., Holden S. A., Ara G., Varshney A., Herman T. S. Interaction of D, L-and D-tetraplatin with hyperthermia in vitro an in vivo. European Journal of Cancer 1992; 28: 794–800
   Google Scholar
• Fisher G., Hahn G. M. Enhancement of cis-platinum (II) diamminechloride cytotoxicity by hyperthermia. National Cancer Inst. Monographs 1982; 61: 255–257
   Google Scholar
• Gasser S. M., Laemmli U. K. Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes of D. Melanogaster. Cell 1986; 46: 521–530
   PubMedGoogle Scholar
• Giocanti N., Hennequin C., Balosso J., Mahler M., et al. DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Research 1993; 53: 2105–2111
   PubMed Web of Science ®Google Scholar
• Goswami P. C., Hill M., Higashikubo R., Wright W. D., Roti J. L. The suppression of the synthesis of a nuclear protein in cells blocked in G2 phase: identification of NP-170 as topoisomerase II. Radiation Research 1992; 132: 162–167
   PubMed Web of Science ®Google Scholar
• Hahn G. M., Braun J., Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42–43°C) and adriamycin (or bleomycin) in mammalian cell inactivation. Proceedings National Academy of Sciences, USA 1975; 72: 937–940
   PubMed Web of Science ®Google Scholar
• Hahn G. M., Li G. C. Interactions of hyperthermia and drugs: treatments and probes. National Cancer Institute of Monographs 1982; 61: 317–323
   PubMedGoogle Scholar
• Hall E. J. Radiobiology for the Radiologist, Ed. 4. Lippencott Co. 1994
   Google Scholar
• Heck M. M. S., Hittelman W. N., Earnshaw W. C. Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. PNAS, USA 1988; 85: 1086–1090
   PubMed Web of Science ®Google Scholar
• Herman T. S. Temperature dependence of adriamycin, cis-diammine-dichloroplatinum, bleomycin and BCN in vitro. Cancer Research 1983; 43: 517–520
   PubMed Web of Science ®Google Scholar
• Hochhauser D., Harris A. L. The laboratory-clinic interface. The role of topoisomerase II α and β in drug resistance. Cancer Treatment Reviews 1993; 19: 181–194
   PubMedGoogle Scholar
• Hsiang Y., Liu L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug campthothecin. Cancer Research 1988; 48: 1722–1726
   PubMed Web of Science ®Google Scholar
• Kalwinsky D. K., Look A. T., Duncore J., Fridland A. Effects of epipodophyllotoxin VP16–213 on cell cycle traverse, DNA synthesis and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Research 1983; 43: 1592–1597
   PubMed Web of Science ®Google Scholar
• Kampinga H. H., Van Den Krick G., Konings A. W. Reduced DNA break formation and cytotoxicity of the toposomerase II drug 4-(9′-acridinylamino) methanesulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines. Cancer Research 1989; 49: 1712–1717
   PubMed Web of Science ®Google Scholar
• Kampinga H. H. Hyperthermia, thermotolerance and topoisomerase II inhibitors. British Journal of Cancer 1995; 72: 333–338
   PubMed Web of Science ®Google Scholar
• Kroll D. J., Borgert C. J., Weidmann T. W., Rowe T. C. Drug sensitivity of heat-resistant mouse B16 melanoma variants. Radiation Research 1990; 124: 15–21
   PubMedGoogle Scholar
• Kubota N., Ketehi M., Inada T. Hyperthermic enhancement of cell killing by five platinum complexes in human melanoma cells grown as monolayer cultures and multicellular spheroids. International Journal of Radiation Oncology Biology and Physics 1993; 25: 491–497
   PubMed Web of Science ®Google Scholar
• Lepock J. Involvement of membranes in cellular responses to hyperthermia. Radiation Research 1982; 92: 433–438
   PubMed Web of Science ®Google Scholar
• Liu L. F. Topoisomerase poisons as antitumor drugs. Annual Reviews in Biochemistry 1989; 58: 351–375
   PubMed Web of Science ®Google Scholar
• Lorico A., Rappa G., Sartorelli A. C. Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cells. International Journal of Cancer 1992; 52: 903–909
   PubMedGoogle Scholar
• Mackey M. A., Anolik S. L., Roti J. L. Cellular mechanisms associated with the lack of chronic thermotolerance expression in Hela S3 cells. Cancer Research 1992; 52: 1101–1106
   PubMed Web of Science ®Google Scholar
• Mackey M. A., Dewey W. C. Cell cycle progression during chronic hyperthermia in S phase CHO cells. International Journal of Hyperthermia 1989; 5: 405–413
   PubMed Web of Science ®Google Scholar
• Matsuo K., Kohno K., Satao S., Uchiumi K. T., Tanimura H., Yamada Y., Kuwano M. Enhanced expression of DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer Research 1993; 53: 1085–1090
   PubMed Web of Science ®Google Scholar
• Mirski S. E. L., Evans C. D., Almquist K. C., Slovak M. L., Cole S. P. C. Altered topoisomerase IIα in a drug resistant small cell lung cancer line selected in VP16. Cancer Research 1993; 53: 4866–4873
   PubMedGoogle Scholar
• Musk S. R. R., Steel G. G. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. British Journal of Cancer 1990; 62: 364–367
   PubMed Web of Science ®Google Scholar
• Ng C. E., Bussey A. M., Raaphorst G. P. Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines. International Journal of Radiation Biology 1994; 66: 49–57
   PubMed Web of Science ®Google Scholar
• Ng C. E., Bussey A. M., MacDonald H. A., Heller D. P., Wilkins D. E., Raaphorst G. P. Cross sensitivity to x-radiation and type I and II DNA topoisomerase inhibitors in a range of human and rodent cell lines. International Journal of Oncology 1995; 7: 1179–1184
   PubMedGoogle Scholar
• Ng C. E., Bussey A. M., Raaphorst G. P. Sequence of treatment is important in the modification of camptothecin induced cell killing by hyperthermia. International Journal Hyperthermia 1996; 12
   Google Scholar
• Pommier Y. DNA topoisomase I and II in cancer chemotherapy: update and perspectives. Cancer chemotherapy and Pharmacology 1993; 32: 103–108
   PubMed Web of Science ®Google Scholar
• Pommier Y., Leteutre F., Fesen M. R., Fujimori A., Bertrand R., Solary E., et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Investigations 1994; 12: 530–542
   PubMed Web of Science ®Google Scholar
• Raaphorst G. P., Feeley M. M., Chu G. L., Dewey W. C. A comparison of the effect of hyperthermia on DNA polymerase in hamster and human glioma cells. International Journal of Hyperthermia 1993; 9: 303–312
   PubMed Web of Science ®Google Scholar
• Rappa G., Lorico A., Sartorelli A. C. Reversal of etoposide resistance in non-P- glycoprotein expressing multidrug resistant tumour cell lines by novobiocin. Cancer Research 1993; 53: 5487–5493
   PubMed Web of Science ®Google Scholar
• Read R. A., Fox M. H., Bedford J. S. The cell cycle dependence of thermotolerance II. CHO cells heated at 45·0°C. Radiation Research 1984; 98: 491–505
   PubMed Web of Science ®Google Scholar
• Ritke M. K., Roberts D., Allan W. P., Raymond J., et al. Altered stability of etoposide-induced topoisomerase II DNA complexes in resistant human leukemia K562 cells. British Journal of Cancer 1994; 69: 687–697
   PubMedGoogle Scholar
• Roberge M., Thing J., Hamaguchi J., Bradbury E. M. The topoisomerase II inhibitor VM-26 induced marked changes in histone HI kinase activity, histones HI and H3 phosphorylation and chromosome condensation in G2 and mitotic BHK cells. Journal of Cell Biology 1990; 111: 1753–1762
   PubMedGoogle Scholar
• Sapareto S. A., Hopwood L. E., Dewey W. C., Faju M. R., Gray J. W. Effect of hyperthermia on survival and progression of CHO cells. Cancer Research 1978; 38: 393–400
   PubMed Web of Science ®Google Scholar
• Schneider E., Horton J. K., Yang C. H., Nakagawa M., et al. Mulitdrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Research 1994; 54: 152–158
   PubMed Web of Science ®Google Scholar
• Slichenmyer W. J., Rowinsky E. K., Donehower R. C., Kaufman S. H. The current status of camptothecin analogues as antitumor agents. JNCI 1993; 85: 271–291
   PubMed Web of Science ®Google Scholar
• Smith P. J., Anderson C. O., Watson J. V. Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts. Cancer Research 1986; 46: 5641–5445
   PubMedGoogle Scholar
• Sullivan D. M., Glisson B. S., Hodges P. K., Smallwood-Kentzo S., Ross W. E. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 1986; 25: 2248–2256
   PubMed Web of Science ®Google Scholar
• Takano H., Kohno K., Ono M., Uchida Y., Kuwano M. Increased phophorylation of DNA topisomerase II in etoposide resistant mutants of human cancer KB cells. Cancer Research 1991; 51: 3951–3957
   PubMed Web of Science ®Google Scholar
• Toffoli G., Bevilacqua C., Franchechin A., Boiocchi M. Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drugresistant P388 leukemia cell lines. International Journal of Hyperthermia 1989; 5: 163–172
   PubMed Web of Science ®Google Scholar
• Trask D. K., Didonato J. A., Mueller M. T. Rapid detection and isolation and covalent DNA/protein complexes: application to topoisomerase I and II. EMBO 1984; 3: 671–676
   PubMed Web of Science ®Google Scholar
• Uemura T., Ohkura H., Adachi Y., Morino K., Shiozaki K., Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 1987; 50: 917–925
   PubMed Web of Science ®Google Scholar
• Urano M., Kahn J., Kenton L. A. Effect of bleomycin on murine tumor cells at elevated temperatures and two different pH values. Cancer Research 1988; 48: 615–619
   PubMed Web of Science ®Google Scholar
• Warters R. L., Barrows L. R. The heat sensitivity of HeLa S3 cell DNA topoisomerase II. Journal of Cell Physiology 1994; 159: 468–474
   PubMed Web of Science ®Google Scholar
• Warters R. L., Brizgys L. M. Effects of topoisomerase II inhibitors on hyperthermic cytotoxicity. Cancer Research 1988; 48: 3932–3938
   PubMed Web of Science ®Google Scholar
• Woesnner R. D., Mattern M. R., Mirabelli C. K., Johnson R. K., Drake F. H. Proliferation and cell-cycle dependent differences in expressions of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth and Differentiation 1991; 2: 209–214
   PubMedGoogle Scholar
• Yang C. J., Horton J. K., Cowan K. H., Schneider E. Cross resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Research 1995; 55: 4004–4009
   PubMed Web of Science ®Google Scholar